$0.71
0.35%
Nasdaq, Fri, Nov 15 2024
ISIN
US10802T1051
Symbol
BBI
Sector
Industry

Brickell Biotech Inc Stock price

$0.71
-0.02 3.06% 1M
-0.19 20.84% 6M
-0.17 18.95% YTD
-0.19 20.83% 1Y
-16.16 95.78% 3Y
-98.29 99.28% 5Y
-3,495.79 99.98% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
+0.00 0.35%
ISIN
US10802T1051
Symbol
BBI
Sector
Industry

Key metrics

Market capitalization $4.26m
Enterprise Value $-6.61m
P/E (TTM) P/E ratio negative
EV/Sales (TTM) EV/Sales -0.83
P/S ratio (TTM) P/S ratio 0.53
P/B ratio (TTM) P/B ratio 0.43
Revenue growth (TTM) Revenue growth 15.31%
Revenue (TTM) Revenue $8.01m
EBIT (operating result TTM) EBIT $-6.36m
Cash position $10.87m
EPS (TTM) EPS $-1.41
Short interest 6.73%
Show more

Is Brickell Biotech Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Brickell Biotech Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Brickell Biotech Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Brickell Biotech Inc:

Buy
100%

Financial data from Brickell Biotech Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '23
+/-
%
8.01 8.01
15% 15%
100%
- Direct Costs 0.08 0.08
-
1%
7.92 7.92
-
99%
- Selling and Administrative Expenses 11 11
23% 23%
138%
- Research and Development Expense 3.18 3.18
77% 77%
40%
-6.28 -6.28
71% 71%
-78%
- Depreciation and Amortization 0.08 0.08
11% 11%
1%
EBIT (Operating Income) EBIT -6.36 -6.36
70% 70%
-79%
Net Profit -5.89 -5.89
72% 72%
-74%

In millions USD.

Don't miss a Thing! We will send you all news about Brickell Biotech Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Brickell Biotech, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. Its pipeline consists of new molecular entities targeting the treatment of the following indications: hyperhidrosis, allergic contact dermatitis, androgenic alopecia, cutaneous t-cell lymphoma and psoriasis. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in 2009 and is headquartered in Boulder, CO.

Head office United States
CEO Albert Marchio
Employees 4
Founded 2009
Website www.frtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today